INiBICA researchers have identified a therapeutic target for the treatment of accelerated aging, known as progeria. The INiBICA group led by Mario Cordero has demonstrated the role of the NLRP3 inflammasome complex in this devastating disease and shown how its potential treatment extends lifespan in animal models. The study, published in the prestigious journal EMBO Molecular Medicine, is part of a project funded by the Progeria Research Foundation.
INiBICA researchers have identified a therapeutic target for the treatment of accelerated aging, known as progeria. The INiBICA group led by Mario Cordero has demonstrated the role of the NLRP3 inflammasome complex in this devastating disease and shown how its potential treatment extends lifespan in animal models. The study, published in the prestigious journal EMBO Molecular Medicine, is part of a project funded by the Progeria Research Foundation.
